Abstract. Glucose transporter 1 deficiency syndrome (GLUT1-DS1) is a rare and complex congenital metabolic encephalopathy characterized by infantile seizures, movement disorder, delayed development and acquired microcephaly. GLUT1-DS1 is most often caused by a de novo heterozygous mutation of the gene encoding the GLUT1 transporter, SLC2A1. We present an otherwise classical case of GLUT1-DS1 presenting at 6 wk of age with seizures. The infant had unexplained neutropenia during the months preceding molecular diagnosis. Mutational analysis of the SLC2A1 gene identified a de novo novel heterozygous deletion of 26 nucleotides between exon 5 and 6. As expected, the treatment with ketogenic diet remedied the seizures, but surprisingly it also corrected the neutropenia. We cannot rule out that this might be a phenomenon of neutropenia as an unexplained association in this single patient, but this novel observation has led us to hypothesize that in a subset of susceptible individuals with GLUT1-DS1, disturbed myelopoieses may be an accompanying phenomenon, which may be explained by deficient energy flux in hematological progenitor cells.
Introduction
Glucose is the most important energy source of the brain in healthy, non-starving children. Decreased glucose supply in a developing brain could have severe consequences for the development of future brain functions [1] . Specific transport proteins facilitate glucose transport across the endothelial blood-brain barrier transport and thereby increase the glucose available to the astrocytes. Several of these proteins have been identified and glucose transporter protein 1 (GLUT1) is the main protein responsible for this transport [1] . GLUT1 is abundantly present in other human cells including cells of hematopoietic origin [2] .
Since the early 1990's more than 150 cases of GLUT1 deficiency syndrome, characterized by early onset infantile seizures, developmental delay, mild movement disorder, acquired microcephaly, mild ataxia, and spasticity have been reported. This symptom complex combined with a persistently low level of the cerebrospinal fluid (CSF)-glucose (hypoglycorrachia) and a decreased CSF-glucose to plasma-glucose ratio has been found to be caused by deficiency of GLUT1, a congenital condition due to a mutation in SLC2A1, the gene encoding the GLUT1 transporter [1] .
The only known effective treatment of GLUT1 deficiency syndrome (GLUT1-DS1, OMIM #606777) is the ketogenic diet. The ketogenic diet is a high fat, low carbohydrate, normocaloric diet, which results in permanent ketosis and provides the brain with an alternative energy substrate. In the vast majority of patients, the ketogenic diet markedly reduces the frequency of seizures and the severity of the movement disorder [1] [2] [3] [4] , and for some patients this diet results in continued normal neurological development.
We present the first reported case of an infant who presented with neutropenia and GLUT1-DS1, whose neutopenia resolved with institution of the ketogenic diet.
Case report
The patient was the first child of unrelated, healthy, Danish parents. Pregnancy, delivery at gestational age 40 wk and 3 days, and neonatal period were uncomplicated. At 6 weeks-old, the boy was brought to the hospital due to observed discoordinated eye movements and head bobbing. He was admitted for observation for 24 hr and then discharged, as no underlying diagnosis was identified. At 8 wk of age, he presented with non-febrile myoclonic seizures. Standard blood tests including C-reactive protein, hemoglobin, thrombocytes, creatinine, sodium, potassium and capillary gas were all normal except for neutropenia (900/mm 3 , reference 1.200-9.600/mm 3 ). Seizures continued, mostly early in the day, in spite of oxcarbazepine treatment titrated to 30 mg/kg/day. The infant had generalized hypotonia and developed several different types of seizures: Initially multifocal myoclonic seizures dominated but later the semiology was characterized by seizures with staring and apnea. At the age of 6 mo, nonepileptic paroxysmal dyskinetic episodes appeared.
Electroencephalography showed focal sharp waves in the right temporal lobe and magnetic resonance scan of the cerebrum revealed delayed frontal myelination, which was also present at a rescan 6 mo later. Urine metabolic screening of amino acids, organic acids, carbohydrates and mucopolysaccharides was normal.
Controls of the neutrophil count revealed persistent neutropenia (Median 700/mm 3 , range 0-3400/mm 3 ). The boy did not encounter any symptoms associated with severe neutropenia e.g. aphtous stomatitis or severe infectious episodes. In response to suspected infections, he was able to respond with a rise of the neutrophil count (Table 1) . The hemoglobin level, monocyte and lymphocyte counts and platelets were persistently within normal limits; the blood smear was normal apart from the neutropenia. A bone marrow examination was not performed. There were no detectable autoimmune antibodies directed against the granulocytes and genetic testing for cyclic neutropenia was negative.
Further blood tests were all normal, including neurometabolic work-up i.e. testing for lysosomal enzyme defects (beta-galactosidase-1 deficiency disease/GM1-gangliosidosis, metachromatic leukodystrophy, Krabbe, Tay-Sach, Sandhoff, fucosidosis, infantile neuronal ceroid lipofuscinoses, mucolipidosis type II), mitochondrial point mutation (mitochondrial DNA deletions, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, neuropathy, ataxia, and retinitis pigmentosa and myoclonic epilepsy with ragged red fibers) and peroxisomal disorders.
In spite of combination treatment initially with oxcarbazepine, then clonazepam and valproate, and finally clonazepam and levetiracetam, seizures continued, albeit with a significant reduction with the latter combination.
At 2 months old, a lumbar puncture revealed a decreased CSF-glucose of 34.2 mg/dL (reference 39.6-70.2 mg/dL). However, the result was not recognized as an indication of GLUT1-DS1. A repeat lumbar puncture with a corresponding plasma glucose at 6.5 mo of age again showed hypoglycorrhachia (34.2 mg/dL), low CSF-lactate level of 0.8 mmol/L (reference 1.1-2.8 mmol/L) and a decreased CSF: plasma-glucose-ratio of 0.4 (normal: 0.5-0.8, GLUT1-DS1: 0.19-0.52, mean 0.37 [4] ). Thus, the patient fulfilled the clinical and biochemical characteristics for GLUT1-DS1 [1] [2] [3] [4] [5] .
The diagnosis was confirmed by molecular genetic testing, which showed a de novo heterozygous deletion in the SLC2A1 gene: Purified polymerase chain reaction products were sequenced using BigDye Terminator cycle sequencing kit v3.1 and the automated sequencer ABI PRISM 3130 DNA Analyzer, (Applied Biosystems, Foster City, CA, USA). This patient was found to carry a heterozygous deletion of 26 nucleotides between exon 5 and exon 6 of SLC2A1 (c.679+25_680-43del; NM_ 006516.2), in silico predicted to affect correct splicing of the GLUT1 protein (NP_006507). The change was not present in the probands parents and was not found in NCBI dbSNP, build 135.
Classical ketogenic diet, ratio 3:1, was started immediately after biochemical diagnosis. The patient was ketotic (measured total blood ketones 3-5.5 mmol/l) after 36 hr. The diet was later adjusted to 2.6:1 ratio to stabilize total blood ketones of 3-5 mmol/l. The child has been seizure-free since the initiation of the diet; the antiepileptic drug therapy was initially reduced to monotherapy with levetiracetam and the child is currently not on any antiepileptic drugs (Table 1) . Surprisingly, the unexplained neutropenia was corrected a few days after initiation of the ketogenic diet. The neutrophil count has remained stable within the normal range (p = 0.012, Student's t-test). The neutrophil counts are presented in Table 1 .
Discussion
The clinical presentation of this patient displaying seizures, movement disorder, delayed cerebral myelinisation, hypoglycorrachia and the lack of response to antiepileptic treatment is consistent with the classical presentation of GLUT1-DS1 [1] [2] [3] [4] [5] . Apart from this classic phenotype, clinical conditions associated with a deficiency of GLUT1 are highly variable and several atypical variants have been portrayed [1] [2] [3] [4] [5] . This patient also presented with severe neutropenia not Hematological adverse events including leukopenia, thrombocytopenia or pancytopenia are rare but well known following antiepileptic treatment with oxcarbazepine, valproate and topiramate [6] .
GLUT1 is the primary glucose transporter of red blood cells and potentially could be associated with anemia [7] and Western blot analysis in erythrocyte membranes and glucose uptake into erythrocytes can be applied to determine GLUT1 function [4, 5] . However except for rare cases of anemia associated with particular mutations in the GLUT1 gene, SLC2A1 [8, 9] , GLUT1-DS1 and hematological disturbances has not previously been described.
In our case, isolated neutropenia was the only hematological abnormality and importantly this was observed prior to any medical treatment. Furthermore, it was independent of changes in anti-epileptic treatment, but with prompt and statistically significant improvement after introduction of ketogenic diet. This novel observation has led us to hypothesize that in a subset of susceptible individuals with GLUT1-DS1, harboring specific mutations in SLC2A1, disturbed myelopoiesis may be an accompanying phenomenon, which may be precipitated by deficient energy flux in myelocytic progenitor cells. A search in the literature did not reveal any data suggesting that ketone bodies work as an alternative fuel in leukocytes as efficiently as in neuronal cells. Finally, we cannot rule out that this might be a phenomenon of neutropenia as an unexplained association in this single patient.
In the international literature the presence of GLUT1 in the cell membrane of human neutrophils has been established [2, [10] [11] [12] . While neutropenia as a feature in GLUT1-DS1 patients has not yet been described, papers implicating that neutrophil function and glucose metabolism are closely linked have been published, though the mechanism is not yet clearly defined [10] [11] [12] . It has furthermore been implied that decreased expression of GLUT isoforms in leukocytes from diabetic patients may impair immune function and predispose to infection in type 2 diabetes [2] . Further studies are needed to elucidate the underlying molecular mechanisms of GLUT1 in myelocytic progenitor cells.
In conclusion, GLUT1-DS1 should be considered as a differential diagnosis in cases of treatment-resistant epilepsy and delayed psychomotor development in preschool children and may be associated with disturbed myelopoiesis.
